Merck Cuts 54 More New Jersey Jobs and Brings Its 2026 State Total to 142

What happened

The Digest reports that Merck will lay off 54 workers at its Rahway location, with the cuts landing in two phases on 11 December 2026 and 4 January 2027. Added to 88 roles removed earlier in the year, that takes the company to 142 New Jersey jobs eliminated in 2026.

The two phase schedule is the informative part. A staged reduction usually signals a function being wound down in an ordered way rather than a blunt percentage cut, with one group holding continuity while the first exits. For anyone in the later wave that is not a reprieve, it is a role the business needs for a few more weeks, and the market they land in is the January market rather than the September one.

There is a practical consequence to that split which is easy to miss. When a reduction is staged across a year boundary, the two groups do not get the same deal in real terms. Health cover, bonus eligibility, holiday accrual and equity vesting all reset or lapse at different points in the calendar, so two people doing identical work can walk away with materially different packages purely because of which side of the new year their date falls on. Anyone with a December date should be asking what changes if that date moves by three weeks, and anyone with a January date should be asking the same question in reverse.

This sits inside something much larger than New Jersey. WFMZ reports the company is cutting approximately 6,000 positions globally, announced in late July 2025, aimed at 3 billion dollars in annual expense reductions by the end of 2027, falling on administrative, sales and research and development roles. The same report notes Pennsylvania exposure as well, including a Northumberland County plant closure announced in March affecting 163 workers.

WFMZ reports roughly 6,000 positions going worldwide, targeting 3 billion dollars in annual savings by the end of 2027.

There is a commercial reason underneath the cost programme, and it is not distress. Patch reports Merck is preparing for the patent expiration of Keytruda, a cancer drug responsible for 40 percent of the company's pharmaceutical sales in 2023, while also facing declining Gardasil demand in China, and is developing a subcutaneous version to extend protection until 2040. That is a company moving money from mature functions toward the thing that replaces its biggest earner.

That reframing matters for how you read your own position. A company protecting itself against a patent cliff is not shrinking, it is reallocating. The money leaving administrative, sales and support functions is going somewhere, and here the destination has been named publicly. Roles attached to the replacement product are the ones being funded, and roles attached to the product being replaced are the ones being counted. The uncomfortable part is that the second group usually contains the people with the deepest knowledge of the business, because they have been there longest.

Where the coverage agrees, and where it splits

Everyone agrees on the programme. The three billion dollar target by the end of 2027 is consistent across The Digest and WFMZ, and both tie the New Jersey filings to it rather than to anything local.

Where the accounts diverge is on how much has actually gone, and that is worth understanding rather than resolving. Different outlets are counting different filings at the same site. WFMZ records 58 positions at Rahway effective in November 2025. Patch records 204 jobs at Rahway between February and May 2026. The Digest records 88 earlier in 2026 plus the 54 now. Those are not contradictions, they are separate notices in a sequence, and that is exactly the point. No single one of them reads as a major layoff. Added together they describe a sustained withdrawal that only becomes visible when you stack the filings.

There is a reporting problem underneath this that affects every worker trying to assess their own risk. State filing databases record notices, not programmes, so a single corporate decision appears as a series of unrelated entries months apart. No outlet is wrong, and no outlet is telling you the whole thing either. The only way to see the shape is to add the filings up yourself, which almost nobody does, and which is precisely why a rolling reduction generates far less alarm than one announcement of the same size.

The company's own framing sits against all of it. WFMZ quotes Merck saying it remains committed to New Jersey, with over 8,000 employees in the state and nearly 3 billion dollars invested there since 2018. Both things are true at once. A large employer can be committed to a state and still be removing roles from it every quarter, and workers should plan against the filings rather than the commitment.

It is not one company either. Patch reports Bristol Myers Squibb cutting 110 positions in Lawrence by mid-March 2026, after 1,156 cuts in 2025, with the two companies together having announced more than 1,200 in 2025. Two of the state's largest pharma employers are trimming on the same timetable.

The sector itself is close to flat. Bureau of Labor Statistics figures put chemical manufacturing employment at about 901,500 in August 2026, having moved only between 898,700 and 901,500 from May to August.

What this means for your job search

The mistake I would most want a Merck employee to avoid is waiting for a resolution that will never be announced. A single cut of 142 roles would be treated as a shock, absorbed, and followed by a recovery narrative. A rolling series of smaller filings produces no such moment, so people wait, and the waiting is the damage. If your employer is running a multi year programme, quiet months are not evidence it has finished.

Here is the test I would apply to my own role in that situation. Ask whether the work would still need doing if the product it supports were discontinued tomorrow, and whether anyone outside your site could do it. Work tied to a mature product, a legacy system or a support function duplicated across sites is a candidate in the next instalment. Work tied to the thing the company has publicly said it is investing in, which here is the subcutaneous Keytruda programme, is on the funded side of the line. That distinction is worth more than any reassurance from a town hall.

Then use the notice period properly. The U.S. Department of Labor requires 60 days notice before a mass layoff and directs employers to notify the state Dislocated Worker Unit as quickly as possible, so Rapid Response is built to reach you before your last day rather than after it. Price yourself honestly while you are still employed, using the chemist median of 88,890 dollars or the chemical technician median of 63,040 dollars as the anchor rather than your current salary. And take the encouraging half of the data seriously, because a sector holding within roughly three thousand jobs across four months is rotating rather than shrinking. The work is moving between employers, not leaving. What a lab technician certification costs and how fast it pays off and showing laboratory skills properly in a job search are the two things that convert a company specific history into a portable one.

Two more things are worth doing while you are still on payroll. Get your internal record straight, because references, performance history and project documentation all become harder to retrieve the day your access is revoked, and a rolling programme means access can go with little warning. And treat your network as the asset it is, since colleagues leaving in the earlier waves are already inside the companies you will be applying to in six months. People who left in February are the best available source of intelligence about where the hiring actually is, and they are usually willing to help someone from the same site.

The broader point I would make to anyone in pharma right now is that employment risk has moved from the company level to the product level. Asking whether your employer is healthy is the wrong question when a healthy employer can still remove your entire function. Asking which product line pays for your role, and how long that product has left, gets you a far more accurate answer, and it is a question you can research without anyone telling you anything.

Finally, be realistic about how long a search in this sector takes. Regulated scientific and quality roles carry longer hiring cycles than most people expect, because the interview loops are deeper and the compliance checks are slower. Starting sixty days before your date is not early, it is roughly on time, and starting on your final day already puts you a month behind the people who read the same filing you did and moved.

Related Articles

• Pharmacist Salary and How to Earn More
• How to Land a Clinical Documentation Specialist Role
• Biology Certifications That Advance Your Science Career
• Laboratory Technician Certification and Your Pathway to Clinical Lab Leadership
• How to Land a Clinical Specialist Role
• New Labor Department Guidance on Overtime and Bonus Pay Explained
• Can Weight-Loss Drugs Boost Employment? Denmark Wants to Find Out
• Getting Laid Off Permanently Changes How You Think About Work
• Skills Training Programs and How to Choose One That Actually Raises Your Pay

People Also Asked

Q: How many jobs is Merck cutting in New Jersey?

A: The Digest reports 54 roles going at Rahway, split across two phases on 11 December 2026 and 4 January 2027, which combined with 88 positions cut earlier in the year brings the 2026 New Jersey total to 142. Other filings at the same site have been reported separately, including 58 positions effective in November 2025 and 204 between February and May 2026.

Q: Why is Merck cutting staff?

A: WFMZ reports a restructuring announced in late July 2025 covering roughly 6,000 positions globally and targeting 3 billion dollars in annual expense reductions by the end of 2027, falling on administrative, sales and research and development roles. Patch adds that the company is preparing for the patent expiry of Keytruda and facing weaker Gardasil demand in China.

Q: Is the pharmaceutical and chemical job market shrinking overall?

A: Not at the sector level. Bureau of Labor Statistics figures put chemical manufacturing employment at about 901,500 in August 2026, having moved only between 898,700 and 901,500 from May to August 2026. Individual employers are reducing while the aggregate stays close to flat, which means the opportunity is rotating between companies rather than leaving the sector.

Looking for your next opportunity? A rolling cost programme means the next filing is a question of when rather than whether, and the people who prepare during the notice period consistently land better than the ones who wait for it to end. Metaintro matches scientific, quality, manufacturing and commercial talent to employers across pharma, devices, diagnostics and specialty manufacturing that are hiring right now. Create a free profile and start mapping your next move today.